| (Values in U.S. Thousands) | Jun, 2024 | Mar, 2024 | Dec, 2023 | Sep, 2023 | Jun, 2023 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -2,320 | -2,010 | -1,020 | -2,960 | -3,340 |
| Net Income Growth | -15.42% | -97.06% | +65.54% | +11.38% | -2.45% |
Kintara Therapeutics Inc (KTRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Kintara Therapeutics Inc. is a biopharmaceutical company. It is focused on the development of new solid tumor cancer therapies. The company's program includes VAL-083 for GBM and REM-001 for cutaneous metastatic breast cancer, which are in clinical stage. Kintara Therapeutics Inc. is based in San Diego, California.